-
公开(公告)号：KR1020000007852A
公开(公告)日：2000-02-07
申请号：KR1019980027384
申请日：1998-07-08
Applicant: 한국화학연구원
CPC classification number: C08J3/14 , B82B3/0095 , C08F220/34
Abstract: PURPOSE: A process for manufacturing nano-granule that is sensitive to temperature and pH by mixing alkyl acrylamide and N,N-dimethylaminoethylmethacrylate and adding a reaction initiator is provided which gives a simple manufacturing method of nano-granule with a uniform size. CONSTITUTION: Alkyl acrylamide and N,N-dimethylaminoethylmethacrylate are melted in a mixed solvent of water and hydrophilic organic solvent in a volume ratio of 9:1-7:3(preferably 9:1) to give a monomer solution, which is added with a reaction initiator and left at about 50-70°C for 10-20 hr(preferably 15), and filtrated. For an example, N,N-dimethylaminoethylmethacrylate is melted in a mixed solvent of water and ethanol in a volume ratio of 7:3 to give 5 weight% of monomer solution, One hundred weight% of monomer solution is mixed with 0.3 weight% of N,N-azobisisobutyronitryl, left at 60°C for 15 hr, and freeze-dehydrated to give a nano granule. As an amount of ethylacrylamide increases, a diameter of nano-granule becomes short.
Abstract translation: 目的：提供通过混合烷基丙烯酰胺和甲基丙烯酸N，N-二甲基氨基乙酯并加入反应引发剂对温度和pH敏感的纳米颗粒的制备方法，其制备具有均匀尺寸的纳米颗粒的简单制造方法。 构成：将丙烯酰胺和甲基丙烯酸N，N-二甲基氨基乙酯在水和亲水性有机溶剂的混合溶剂中以9：1-7：3（优选9：1）的体积比熔化，得到单体溶液，加入 反应引发剂，并在约50-70℃下放置10-20小时（优选15℃），并过滤。 例如，将甲基丙烯酸N，N-二甲基氨基乙酯在水和乙醇的混合溶剂中以体积比为7:3进行熔融，得到5重量％的单体溶液，将100重量％的单体溶液与0.3重量％ N，N-偶氮二异丁腈，在60℃下放置15小时，冷冻脱水，得到纳米颗粒。 随着乙基丙烯酰胺的量增加，纳米颗粒的直径变短。
-
公开(公告)号：KR1019960030931A
公开(公告)日：1996-09-17
申请号：KR1019950003712
申请日：1995-02-24
Applicant: 한국화학연구원
Abstract: 고분자 및 단분자가 용해되어 있는 수용액과 기름을 혼합하여 o/w 에멀젼 제조하고 이 에멀젼을 용액에 약물과 기타 첨가물들을 혼합하며 사용되는 고분자에 따라 금속이온 가교, UV를 이용한 가교 및 냉각 등을 사용하여 혼합 용액을 고형화한 후 용도에 부합하는 형태로 성형한 에밀젼 네트웍을 이용한 피부 약물 전달 체계는 제조공정이 간단하며, 다양한 약물에 대해서 적용이 가능한 우수한 피부 약물 전달 체계이다.
-
公开(公告)号：KR1019960011044B1
公开(公告)日：1996-08-16
申请号：KR1019930019898
申请日：1993-09-27
Applicant: 한국화학연구원
IPC: B01D69/00
CPC classification number: A61K9/7084 , B01D67/0002 , B01D71/26 , B01D71/38 , B01D71/40 , B01D71/76 , C08J9/26
Abstract: The membrane is made by; (a) dissolving biocompatible non-allergenic polymer such as ethylene- vinylacetate copolymer, ethylene-vinylalcohol copolymer, ethylene-ethylacrylate copolymer or ethylene-vinyloxyethanol copolymer in methylenechloride; (b)dissolving polyalcohol compound such as hydroxypropylcellulose, hydroxypropylmethylcellulose, polyethylene glycol, glycerine or ethylene glycol in the mixture of alkanol such as ethanol, propanol, butanol, pentanol or octanol and gloride; (c) mixing (a) and (b) with homogenizer; (d) applying it to the glass to uniform thickness; (e) drying.
Abstract translation: 膜由...制成 （a）在二氯甲烷中溶解生物相容性非过敏性聚合物如乙烯 - 乙酸乙烯酯共聚物，乙烯 - 乙烯醇共聚物，乙烯 - 丙烯酸乙酯共聚物或乙烯 - 乙烯基氧乙醇共聚物; （b）将诸如羟丙基纤维素，羟丙基甲基纤维素，聚乙二醇，甘油或乙二醇的多元醇化合物溶解在链烷醇如乙醇，丙醇，丁醇，戊醇或辛醇和氯化物的混合物中; （c）用均化器混合（a）和（b）; （d）将其施加到玻璃以均匀的厚度; （e）干燥。
-
公开(公告)号：KR1019960006730B1
公开(公告)日：1996-05-23
申请号：KR1019930001880
申请日：1993-02-11
Applicant: 한국화학연구원
IPC: A61K9/70
Abstract: The transdermal drug delivery system is composed of the steps of; (a) obtaining the oil phase material containing medicine by mixing medicine and oily material; (b) obtaining O/W emulsion containing oil particles with a diameter of 1-5 Pm by mixing the oil phase material and biodegradable and bioacceptable polymer solution, containing polysaccharide to chelate with metals such as sodium alginate, pectin, xanthomonas campestris or carboxymethylcellulose, and decomposable biologically, with homogenizer; (c) casting the emulsion on glass plate; (d) inducing coupling between the polyvalent ion and the polysaccharide by adding polyvalent ion to the glass plate; (e) leaving it for 301min. and drying.
Abstract translation: 透皮给药系统由以下步骤组成： （a）通过混合药物和油性物质获得含有药物的油相材料; （b）通过将油相材料和生物可降解和生物可接受的聚合物溶液混合，得到含有直径为1-5Pm的油颗粒的O / W乳液，其含有多糖与金属如藻酸钠，果胶，油菜黄单孢菌或羧甲基纤维素螯合， 用生物学分解，用均化器; （c）将乳液浇铸在玻璃板上; （d）通过向玻璃板中加入多价离子来诱导多价离子和多糖之间的偶联; （e）离开301min。 并干燥。
-
公开(公告)号：KR1019950031053A
公开(公告)日：1995-12-18
申请号：KR1019940010116
申请日：1994-05-09
Applicant: 한국화학연구원
IPC: A61K9/70
Abstract: 인터피너트레이팅 네트웍(Interpenetrating Networks : IPNs)의 개념을 이용하여 이온 농도가 극대화된 이온성 고분자 젤을 개발하고 특정한 pH조건에서 약물을 이온화하여 이온결합 형태로 이온성 고분자젤 내에 충전한 피부약물전달체계는 시스템에서 가장 중요한 부분인 이온성 고분자 젤내의 이온성 기의 증가로 약물의 충진율이 극대화되어 약물의 충진율의 조절이 아주 용이하고 약물 방출율이 매트릭스내에서의 약물의 자체확산과 고분자 매트릭스 내에 이온기와 약물의 이온 결합의 형성과 분해에 의하여 조절되기 때문에 조절적인 약물의 방출율을 나타내는 발전된 형태의 피부약물전달체계를 제공한다.
-
Patent Agency Ranking
-
公开(公告)号：KR100411195B1
公开(公告)日：2003-12-18
申请号：KR1020000056496
申请日：2000-09-26
Applicant: 한국화학연구원
IPC: A61K9/24
Abstract: PURPOSE: Provided is a controlled release pellet containing ketorolac tromethamine, thereby reducing dosage and consequently increasing drug stability and decreasing side effects. CONSTITUTION: The controlled release pellet containing ketorolac tromethamine characteristically consists of a crystalline core(1) having a size of 300-1000 micrometer, an inner layer(2) including ketorolac tromethamine, and a controlled release type of outer layer(3) containing Eudragit as an essential ingredient and optionally a water-soluble polymer.
Abstract translation: 目的：提供含有酮咯酸氨丁三醇的控释小丸，由此减少剂量并因此增加药物稳定性并减少副作用。 构成：含有酮咯酸氨丁三醇的控释小丸特征性地由尺寸为300-1000微米的晶体核（1），包含酮咯酸氨丁三醇的内层（2）和含Eudragit的控释型外层（3）组成 作为必要成分和任选的水溶性聚合物。
-
公开(公告)号：KR1020020024714A
公开(公告)日：2002-04-01
申请号：KR1020000056496
申请日：2000-09-26
Applicant: 한국화학연구원
IPC: A61K9/24
CPC classification number: A61K9/1676 , A61K31/407
Abstract: PURPOSE: Provided is a controlled release pellet containing ketorolac tromethamine, thereby reducing dosage and consequently increasing drug stability and decreasing side effects. CONSTITUTION: The controlled release pellet containing ketorolac tromethamine characteristically consists of a crystalline core(1) having a size of 300-1000 micrometer, an inner layer(2) including ketorolac tromethamine, and a controlled release type of outer layer(3) containing Eudragit as an essential ingredient and optionally a water-soluble polymer.
Abstract translation: 目的：提供含有酮咯酸氨丁三醇的控释丸，从而减少剂量，从而增加药物稳定性和减少副作用。 构成：含有酮咯酸氨丁三醇的控制释放颗粒特征性地由尺寸为300-1000微米的结晶核心（1），包含酮咯酸氨丁三醇的内层（2）和含有Eudragit的控释型外层（3）组成 作为必需成分和任选的水溶性聚合物。
-
公开(公告)号：KR1020000046614A
公开(公告)日：2000-07-25
申请号：KR1019980063311
申请日：1998-12-31
Applicant: 한국화학연구원
IPC: A61K47/30
Abstract: PURPOSE: A drug transmission carrier composition useful in preparing a gel matrix, microspheres, or fibers with excellent drug penetration and strength, and a preparation method thereof are provided. CONSTITUTION: A drug delivery carrier composition consists of a carrier compound such as polyvinyl alcohol and subsidiary dissolving agents such as diethylene glycolmonoethyl ether, ethylene glycol monoethyl ether and ethylene glycol monomethyl ether. Soluble polymer such as polyalkyl glycol compounds, polyacrylic acid, polyvinyl pyrolidone, sodium alginate, and gelatine may be added to improve the strength of the composition,. The method for producing carrier composition comprises the steps of: dissolving polyvinyl in distilled water; and adding subsidiary dissolving agents to the mixed solution.
Abstract translation: 目的：提供一种可用于制备具有优异的药物渗透性和强度的凝胶基质，微球或纤维的药物传播载体组合物及其制备方法。 构成：药物递送载体组合物由聚乙烯醇等载体化合物和二乙二醇单乙醚，乙二醇单乙醚，乙二醇单甲醚等辅助溶解剂组成。 可以加入可溶性聚合物如聚烷基二醇化合物，聚丙烯酸，聚乙烯吡咯烷酮，藻酸钠和明胶，以提高组合物的强度。 制备载体组合物的方法包括以下步骤：将聚乙烯醇溶解在蒸馏水中; 并向混合溶液中加入辅助溶解剂。
-
-
-
-
-
-
-
-
-
Search Results
53
records
(took 0.022 seconds)
